Table 1.

Relationship between the expression of miR-148a and clinicopathological features in hepatocellular carcinoma (HCC) $\left(\overline{\mathit{x}}\mathbf{\pm }\mathit{s}\right)$

Clinicopathological features		n	MiR-148a relevant expression
			2 -△cq	t	P
Tissue	HCC	89	0.87 ± 0.50	−7.762∆	< 0.001
	Adjacent noncancerous liver	89	1.44 ± 0.61
Age	≥ 50	43	0.83 ± 0.49	−0.727	0.469
	< 50	46	0.91 ± 0.51
Gender	Male	72	0.88 ± 0.50	0.392	0.696
	Female	17	0.83 ± 0.53
Differentiation	Well	6	0.88 ± 0.40	F = 0.531a	0.590
	Moderately	57	0.91 ± 0.52
	Poorly	26	0.79 ± 0.48
Clinical TNM stage	I to II	19	1.17 ± 0.58	3.106	0.003
	III to IV	70	0.79 ± 0.45
Metastasis	Yes	46	0.74 ± 0.51	−2.537	0.013
	No	43	1.00 ± 0.46
With cirrhosis	Yes	43	0.86 ± 0.52	−0.143	0.886
	No	46	0.88 ± 0.48
AFP (μg/L)	≥ 400	35	0.90 ± 0.51	−0.015	0.988
	< 400	38	0.90 ± 0.49
Portal vein tumor embolus	Yes	29	0.76 ± 0.53	−1.400	0.165
	No	60	0.92 ± 0.48
Tumor capsular infiltration	No capsular or capsular infiltration	48	0.76 ± 0.49	−2.308	0.023
	No capsular infiltration	41	1.00 ± 0.49
Tumor nodes	Multiple	40	0.75 ± 0.47	−2.015	0.047
	Single	49	0.96 ± 0.51
Tumor diameter (cm)	≥ 5	73	0.91 ± 0.51	1.515	0.133
	< 5	15	0.70 ± 0.46
Vaso-invasion	Yes	32	0.79 ± 0.53	−1.116	0.267
	No	56	0.92 ± 0.49
HBV infection	Yes	73	0.84 ± 0.51	−1.347	0.181
	No	16	1.02 ± 0.45
HCV infection	Yes	29	0.94 ± 0.51	0.912	0.364
	No	60	0.84 ± 0.50

∆Paired t-student test was performed.

^aOne-way analysis of variance (ANOVA) test was performed.